Biologics Supplier for Medspas & Dermatology in Fayetteville, AR

Medical-director oversight for medspa accounts

Medspas ordering through Precision Biologics must operate under physician supervision, and we ask for the supervising physician's NPI number at account setup. This mirrors how medspas typically structure vendor relationships for other physician-only product categories, with the medical director as the named point of accountability.

Dermatology and plastic surgery practices that order directly under their own NPI follow the same verification step, just without the separate medical-director layer.

What to request before adding a new product line

Ask for the lot-specific certificate of analysis, the donor eligibility summary, and the third-party sterility testing result for any Wharton's jelly allograft. For exosome products, request the supplier-reported characterization data, which for Precision Biologics' line includes particle concentration by nanoparticle tracking analysis and markers identified by ELISA and SP-IRIS.

• Certificate of analysis, by lot
• Donor eligibility summary
• Sterility testing result
• Characterization data for exosome products (NTA, ELISA, SP-IRIS)

Cold-chain and shelf-stable shipping

Cryopreserved Wharton's jelly products ship overnight on dry ice in validated containers and need -80 degree C storage on arrival, which works best for practices with a dedicated ultra-low freezer. Lyophilized exosome products are shelf-stable under normal storage conditions, which several medspas prefer for lower-volume stocking.

Either format is tracked by lot from the point it leaves our facility through the point your staff logs it against a patient record.

Scope of practice and regulatory review

Precision Biologics does not advise on injection technique, dosing, or which intended uses a given product supports. Confirm your practice's scope of practice and physician supervision requirements with the Arkansas medical board before adding a new biologic category, and route any 21 CFR 1271.10 or exosome-regulation questions to your own counsel.

We support that process with documentation and a peer-to-peer call for your medical director, not with clinical guidance.

FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.

These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.